SAN DIEGO--(BUSINESS WIRE)--Endeavor BioMedicines, a clinical-stage company developing therapies for of fibrotic disease and oncology, today announced the appointment of Paul Frohna, M.D., Ph.D., as its Chief Medical Officer. Dr. Frohna is a physician-scientist with over 20 years of experience in the biotech industry in the fields of translational medicine, clinical trial design, and clinical and regulatory strategy..

圣地亚哥-（商业线）-Endeavor BioMedicines是一家开发纤维化疾病和肿瘤学治疗方法的临床阶段公司，今天宣布任命Paul Frohna博士，博士为其首席医疗官。Frohna博士是一位医学科学家，在转化医学，临床试验设计以及临床和监管策略等领域拥有20多年的生物技术行业经验。。

“We’re pleased to welcome Paul as our Chief Medical Officer, and we look forward to his leadership as we progress our pipeline of therapies for patients with fibrosis and cancer,” said John Hood, Ph.D., Co-Founder, CEO and Chairman, Endeavor BioMedicines. “Paul’s deep experience as a physician-scientist and impressive track record in clinical development and translational medicine will be valuable additions to Endeavor as we advance our programs, including our Phase 2 trial of ENV-101 in idiopathic pulmonary fibrosis (IPF) and the first-in-human trial for our HER3-targeted ADC in oncology.”.

“我们很高兴欢迎保罗作为我们的首席医疗官，我们期待他的领导，因为我们为纤维化和癌症患者推进我们的治疗方案，”John Hood博士，联合创始人兼首席执行官兼主席Endeavor BioMedicines说。“随着我们推进我们的项目，包括我们的ENV-101在特发性肺纤维化（IPF）中的2期临床试验和我们在肿瘤学HER3靶向ADC的人体试验“。

Dr. Frohna joins Endeavor from ImCheck Therapeutics in Marseille, France, where he served as Chief Medical Officer and Head of Research and Development responsible for overseeing programs in oncology and infectious disease. Prior to ImCheck, he was Chief Medical Officer at Bioniz Therapeutics, where he led clinical and regulatory affairs functions and was responsible for operational oversight of the company's clinical programs in T-cell leukemia and lymphoma as well as autoimmune diseases.

Frohna博士加入了法国马赛ImCheck Therapeutics的努力，在那里他担任首席医疗官和研究与开发负责监督肿瘤学和传染病项目。在ImCheck之前，他是Bioniz Therapeutics的首席医疗官，在那里他领导临床和监管事务职能，并负责对公司在T细胞白血病和淋巴瘤以及自身免疫性疾病方面的临床计划进行业务监督。

Prior to this role, he held senior roles at Receptos Inc., ProFibrix, Inc. and Fibrogen. Dr. Frohna began his biotech career at Genentech where he patented and initially tested the therapeutic approach of B-cell depleting therapy for relapsing and progressive multiple sclerosis..

在此职位之前，他曾在Receptos Inc.，ProFibrix，Inc.和Fibrogen担任高级职位。Frohna博士在Genentech开始了他的生物技术生涯，在那里他获得了专利并最初测试了B细胞耗竭疗法治疗复发和进行性多发性硬化症的治疗方法。。

“It is a privilege to join Endeavor as the company enters its next stage of growth,' said Dr. Frohna. “I look forward to contributing my clinical development experiences in fibrosis and oncology to demonstrate the therapeutic promise of our pipeline of medicines in order to help patients who deserve better treatments for their deadly diseases.”.

“当公司进入下一个发展阶段时，加入努力是一种特权，”Frohna博士说：“我期待为我在纤维化和肿瘤学方面的临床开发经验做出贡献，以展示我们的药物管道的治疗前景，以帮助那些因其致命疾病而值得更好治疗的患者“。

Over the course of his career, Dr. Frohna has built and led departments and teams responsible for candidate selection, IND/CTA filings, Phase I to III clinical trials and global development partnerships. He has successfully designed and initiated translational and clinical programs for biologics, small molecules and stem cells across multiple therapeutic areas.

在他的职业生涯中，Frohna博士建立并领导了负责候选人选择，IND/CTA申请，I至III期临床试验和全球发展伙伴关系的部门和团队。他已成功设计并启动了跨多个治疗领域的生物制剂，小分子和干细胞的转化和临床计划。

He played critical roles in multiple development programs including Receptos' ozanimod (Zeposia® marketed by BMS), Profibrix’s Raplixa™ and Genentech's Rituxan®, Tarceva® and Raptiva® programs. Dr. Frohna received his pharmacy degree from the University of Texas at Austin College of Pharmacy, his Ph.D.

他在多个发展项目中发挥了关键作用，包括Receptos的ozanimod（由BMS销售的Zeposia），Profibrix的Raplixa™ 以及Genentech的Rituxan®，Tarceva®和Raptiva®程序。Frohna博士在德克萨斯大学奥斯汀药学院获得药学学位，获得博士学位。

in Pharmacology from the University of Pennsylvania School of Medicine, and his M.D. from Georgetown University School of Medicine..

宾夕法尼亚大学医学院药理学系，乔治敦大学医学院医学博士。。

About Endeavor BioMedicines

关于努力生物医学

Endeavor BioMedicines, Inc., is a clinical stage company developing novel therapies for fibrosis and oncology. We combine best-in-class therapeutics with an evolved understanding of terminal diseases to develop medicines with the potential to reverse severe health conditions. Our lead program, ENV-101, is a Hedgehog signalling inhibitor currently in Phase 2 studies treating IPF.

Endeavor BioMedicines，Inc。是一家开发纤维化和肿瘤学新疗法的临床阶段公司。我们将一流的治疗方法与对终末期疾病的不断了解相结合，开发出具有逆转严重健康状况潜力的药物。我们的领导计划ENV-101是目前正在治疗IPF的2期研究中的刺猬信号抑制剂。

The second program is a HER3-targeted ADC that will begin clinical development in 2024 for the treatment of multiple solid tumors. At Endeavor, we are an innovative and focused team that has come together to develop therapeutics that help patients feel better and live longer. Please visit us on our website at www.endeavorbiomedicines.com and on our LinkedIn and X (formerly Twitter) pages..

第二个计划是HER3靶向ADC，将于2024年开始临床开发，用于治疗多种实体瘤。在努力中，我们是一个创新和专注的团队，共同开发治疗方法，帮助患者感觉更好，寿命更长。请访问我们的网站www.endeavorbiomedicines.com以及我们的LinkedIn和X（以前的Twitter）页面。。